162 related articles for article (PubMed ID: 32821295)
21. Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis.
Mincu RI; Mahabadi AA; Michel L; Mrotzek SM; Schadendorf D; Rassaf T; Totzeck M
JAMA Netw Open; 2019 Aug; 2(8):e198890. PubMed ID: 31397860
[TBL] [Abstract][Full Text] [Related]
22. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
23. [MEK inhibitor-associated retinopathy under binimetinib treatment for cutaneous malignant melanoma].
Groselli S; Heinrich D; Lohmann CP; Maier M
Ophthalmologe; 2021 Feb; 118(2):169-174. PubMed ID: 32248296
[TBL] [Abstract][Full Text] [Related]
24. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754
[TBL] [Abstract][Full Text] [Related]
25. Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.
Niro A; Strippoli S; Alessio G; Sborgia L; Recchimurzo N; Guida M
Am J Ophthalmol; 2015 Nov; 160(5):959-967.e1. PubMed ID: 26231307
[TBL] [Abstract][Full Text] [Related]
26. A 66-year-old woman with two weeks of distorted vision in the left eye.
Griffin S; McDonald HR; Agarwal A
Retin Cases Brief Rep; 2023 Nov; ():. PubMed ID: 37910636
[TBL] [Abstract][Full Text] [Related]
27. Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.
Keating GM
Drugs; 2016 Apr; 76(5):605-15. PubMed ID: 26984388
[TBL] [Abstract][Full Text] [Related]
28. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
[TBL] [Abstract][Full Text] [Related]
29. Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma.
Consoli F; Bersanelli M; Perego G; Grisanti S; Merelli B; Berruti A; Petrelli F
Clin Transl Oncol; 2020 Jun; 22(6):900-907. PubMed ID: 31555967
[TBL] [Abstract][Full Text] [Related]
30. Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy.
Francis JH; Canestraro J; Haggag-Lindgren D; Harding JJ; Diamond EL; Drilon A; Li BT; Iyer G; Schram AM; Abramson DH
Ophthalmol Retina; 2021 Dec; 5(12):1187-1195. PubMed ID: 34102344
[TBL] [Abstract][Full Text] [Related]
31. Panniculitis Associated with MEK Inhibitor Therapy: An Uncommon Adverse Effect.
Negulescu M; Deilhes F; Sibaud V; Tournier E; Lamant L; Boulinguez S; Meyer N
Case Rep Dermatol; 2017; 9(1):80-85. PubMed ID: 28611627
[TBL] [Abstract][Full Text] [Related]
32. BRAF and MEK inhibition in melanoma.
Dossett LA; Kudchadkar RR; Zager JS
Expert Opin Drug Saf; 2015 Apr; 14(4):559-70. PubMed ID: 25648338
[TBL] [Abstract][Full Text] [Related]
33. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Daud A; Tsai K
Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
[TBL] [Abstract][Full Text] [Related]
34. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA
BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658
[TBL] [Abstract][Full Text] [Related]
35. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.
van der Hiel B; Haanen JBAG; Stokkel MPM; Peeper DS; Jimenez CR; Beijnen JH; van de Wiel BA; Boellaard R; van den Eertwegh AJM;
BMC Cancer; 2017 Sep; 17(1):649. PubMed ID: 28915798
[TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF
Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924
[TBL] [Abstract][Full Text] [Related]
37. Choriocapillaris Assessment In Patients Under Mek-Inhibitor Therapy For Cutaneous Melanoma: An Optical Coherence Tomography Angiography Study.
Fasolino G; Awada G; Koulalis JS; Neyns B; Van Elderen P; Kuijpers RW; Nelis P; Ten Tusscher M
Semin Ophthalmol; 2021 Nov; 36(8):765-771. PubMed ID: 33755528
[TBL] [Abstract][Full Text] [Related]
38. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF
Gutzmer R; Stroyakovskiy D; Gogas H; Robert C; Lewis K; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Manikhas GM; Yan Y; Huang KC; Uyei A; McNally V; McArthur GA; Ascierto PA
Lancet; 2020 Jun; 395(10240):1835-1844. PubMed ID: 32534646
[TBL] [Abstract][Full Text] [Related]
39. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
[TBL] [Abstract][Full Text] [Related]
40. Rapidly Changing Serous Detachment During BRAF and MEK Inhibitor Therapy.
Agata C; Kitamoto K; Ueda K; Azuma K; Inoue T; Obata R
Cureus; 2021 Dec; 13(12):e20491. PubMed ID: 35070538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
